Large subretinal hemorrhage after intravitreal bevacizumab (Avastin) for age-related macular degeneration.
We report the development of a large subretinal hemorrhage 4 weeks after intravitreal bevacizumab in an 84-year-old male with 20/70 visual acuity caused by occult choroidal neovascularization from neovascular age-related macular degeneration in one eye that was treated with 1.25 mg of intravitreal bevacizumab.
Chieh
Jenet J
JJ
Department of Opthalmology, Duke University Medical Center, Durham, NC 27710, USA.
Fekrat
Sharon
S
D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004333:Drug Administration Routes; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D012166:Retinal Hemorrhage / Q000175:diagnosis / Q000209:etiology* / Q000473:pathology; D014786:Vision Disorders / Q000175:diagnosis / Q000209:etiology / Q000473:pathology; D014822:Vitreous Body / Q000187:drug effects / Q000473:pathology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab